A case report of sarcomatoid hepatocellular carcinoma treated multimodality

Cam Phuong Pham; Quang Hien Le; Binh Duong Nguyen; Trong Khoa Mai; Van Thai Pham; Thi Hong Lieu Nguyen

doi:10.36922/ARNM025220024

Advances in Radiotherapy & Nuclear Medicine ›› 2025, Vol. 3 ›› Issue (3) :94 -99. DOI: 10.36922/ARNM025220024

CASE REPORT

research-article

A case report of sarcomatoid hepatocellular carcinoma treated multimodality

Author information +

History +

PDF

Abstract

Sarcomatoid hepatocellular carcinoma (SHC) is a rare and highly aggressive variant of hepatocellular carcinoma (HCC), characterized by high malignancy, frequent recurrence, and poor prognosis. Definitive diagnosis is based on histopathological criteria to differentiate it from HCC and other malignant tumors in the liver. At present, there is no standardized treatment; surgery remains the primary therapeutic option, while other treatments show only modest effectiveness. We herein present a clinical case of a male patient diagnosed with SHC who experienced multiple recurrences and underwent multimodal treatment, including transarterial chemoembolization, surgery, and systemic chemotherapy.

Keywords

Sarcomatoid hepatocellular carcinoma / Recurrence / Multimodality treatment

Cite this article

Download citation ▾

Cam Phuong Pham, Quang Hien Le, Binh Duong Nguyen, Trong Khoa Mai, Van Thai Pham, Thi Hong Lieu Nguyen. A case report of sarcomatoid hepatocellular carcinoma treated multimodality. Advances in Radiotherapy & Nuclear Medicine, 2025, 3(3): 94-99 DOI:10.36922/ARNM025220024

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	1. Yu Y, Zhong Y, Wang J, Wu D. Sarcomatoid hepatocellular carcinoma (SHC): A case report. World J Surg Oncol. 2017; 15(1):219. doi: 10.1186/s12957-017-1286-1

[2]	2. Zhang C, Feng S, Tu Z, et al. Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome. Cancer Med. 2021; 10(18):6227-6238. doi: 10.1002/cam4.4162

[3]	3. Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: A special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989; 23(S1): S4-S8. doi: 10.1007/BF00647229

[4]	4. Marijon H, Dokmak S, Paradis V, et al. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol. 2011; 54(5):1073-1078. doi: 10.1016/j.jhep.2010.11.011

[5]	5. Obara K, Matsumoto N, Okamoto M, et al. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008; 2(1):116-123. doi: 10.1007/s12072-007-9040-3

[6]	6. Lee KB. Sarcomatoid hepatocellular carcinoma with mixed osteoclast-like giant cells and chondroid differentiation. Clin Mol Hepatol. 2014; 20(3):313-316. doi: 10.3350/cmh.2014.20.3.313

[7]	7. Li J, Gao X, Zhao K, Meng X, Liu S, Zhang J. Hepatocellular carcinoma combined with sarcomatoid hepatocellular carcinoma: A case report. Medicine (Baltimore). 2024; 103(4):e37013. doi: 10.1097/MD.0000000000037013